HURA
$2.08
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.
Intraday
Recent News
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake
NasdaqCM:HURA 1 Year Share Price vs Fair Value Explore TuHURA Biosciences's Fair Values from the Community and select...
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial
TuHURA Biosciences (HURA) said Monday that updated results from Kineta's VISTA-101, a Phase I/II fir
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where TuHURA Biosciences, Inc. (NASDAQ:HURA) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...